Clinical Trial

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to identify the optimal dose level of NP-G2-044 in combination with standard of care (SOC) pegylated liposomal doxorubicin (PLD), and to compare the efficacy and safety of NP-G2-044+PLD vs. PLD alone in participants with platinum-resistant ovarian cancer (PROC).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2025-07-31; most recent amendment 2026-03-05.
Status change: Recruiting → Active, Not Recruiting 2026-03-05
Status change: Not Yet Recruiting → Recruiting 2025-09-26
Trial Details
NCT Number NCT07109414
Lead Sponsor Novita Pharmaceuticals, Inc.
Collaborators: Gynecologic Oncology Group
Conditions Platinum-resistant Ovarian Cancer
Enrollment 380 participants
Start Date 2025-12-29
Primary Completion 2028-10-25 (estimated)
Study Completion 2029-10-24 (estimated)
Updated on ClinicalTrials.gov 2026-03-09